Biochemical aspects of experimentally induced parkinsonism.
D006916:5-Hydroxytryptophan / Q000494:pharmacology; D000588:Amines / Q000378:metabolism*; D000596:Amino Acids / Q000378:metabolism; D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001058:Apomorphine / Q000627:therapeutic use; D001479:Basal Ganglia / Q000378:metabolism; D001679:Biogenic Amines / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D002262:Carboxy-Lyases / Q000378:metabolism; D065098:Catechol O-Methyltransferase Inhibitors; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D004195:Disease Models, Animal; D004298:Dopamine / Q000494:pharmacology; D004299:Dopamine beta-Hydroxylase / Q000097:blood / Q000378:metabolism; D000882:Haplorhini; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D051381:Rats; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D014793:Visual Cortex / Q000201:enzymology
D000588:Amines; D000596:Amino Acids; D000978:Antiparkinson Agents; D001679:Biogenic Amines; D065098:Catechol O-Methyltransferase Inhibitors; D008996:Monoamine Oxidase Inhibitors; D004295:Dihydroxyphenylalanine; D006916:5-Hydroxytryptophan; D014446:Tyrosine 3-Monooxygenase; D004299:Dopamine beta-Hydroxylase; D002262:Carboxy-Lyases; D001058:Apomorphine; D004298:Dopamine